Active, not recruitingPhase 3NCT02455141
Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer
Studying Cerebrotendinous xanthomatosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Principal Investigator
- Kunwei Shen, professorAffiliated Ruijin Hospital of Shanghai JiaoTong University School of Medicine
- Intervention
- Epirubicin plus Cyclophosphamide(drug)
- Enrollment
- 786 target
- Eligibility
- 18-70 years · FEMALE
- Timeline
- 2016 – 2030
Study locations (27)
- Fuding Hospital, Fuding, Fujian, China
- The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
- Quanzhou First Hospital, Quanzhou, Fujian, China
- Foshan No.1 People's Hospital, Foshan, Guangdong, China
- Guangdong Maternal and Child Health Care Hospital, Guangzhou, Guangdong, China
- Cancer Hospital Affiliated to Harbin Medical University, Harbin, Heilongjiang, China
- Jiangsu Jiangyin People's Hospital, Jiangyin, Jiangsu, China
- The First People's Hospital of Wujiang District, Suzhou, Jiangsu, China
- Yancheng Hospital of TCM, Yancheng, Jiangsu, China
- Obstetrics & Gynecology Hospital of Fudan University, Shanghai, Shanghai Municipality, China
- Shanghai JiaoTong University School of Medicine, Ruijin Hospital, Shanghai, Shanghai Municipality, China
- Central Hospital of Huangpu District, Shanghai, Shanghai, Shanghai Municipality, China
- Shanghai International Peace Maternal and child health care hospital, Shanghai, Shanghai Municipality, China
- The Ninth People's Hospital of Shanghai, Shanghai, Shanghai Municipality, China
- Hangzhou Cancer Hospital, Hangzhou, Zhejiang, China
- +12 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02455141 on ClinicalTrials.govOther trials for Cerebrotendinous xanthomatosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07510802Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBCBeijing Biotech
- RECRUITINGPHASE1NCT07162038Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell TransplantationNational Cancer Institute (NCI)
- RECRUITINGNANCT06790225Glucose-dependent INsulinotropic Polypeptide: Effect on Bone Remodelling and Cell Activity (GINEBRA)Esbjerg Hospital - University Hospital of Southern Denmark
- RECRUITINGPHASE2NCT05909059CAR T-cell Therapy in Patients With Renal DysfunctionNorthside Hospital, Inc.
- RECRUITINGPHASE2NCT06042569Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY TrialCity of Hope Medical Center
- RECRUITINGPHASE1, PHASE2NCT06594640R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell LymphomaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1NCT05748197A Study of ADCLEC.syn1 in People With Acute Myeloid LeukemiaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE3NCT05883852EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast CancerFudan University